Related references
Note: Only part of the references are listed.Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients
Michael Davidson et al.
CLINICAL COLORECTAL CANCER (2018)
Genomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategies
Alessandra Raimondi et al.
PHARMACOGENOMICS (2018)
Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment
E. An et al.
ANNALS OF ONCOLOGY (2017)
Efficacy and safety of taxane-based systemic chemotherapy of advanced gastric cancer: A systematic review and meta-analysis
Jinxin Shi et al.
SCIENTIFIC REPORTS (2017)
Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer
Maria Di Bartolomeo et al.
GASTRIC CANCER (2016)
High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy
Paolo Nuciforo et al.
MOLECULAR ONCOLOGY (2016)
Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study
Zhi-Liang Huang et al.
ONCOLOGY LETTERS (2016)
Domain-Specific c-Met Measurement by Quantitative Immunofluorescence and Mass Spectrometry in Non-Small Cell Lung Cancer
Maria Toki et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Quantification of HER2 by Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded (FFPE) Breast Cancer Tissues
Carine Steiner et al.
MOLECULAR & CELLULAR PROTEOMICS (2015)
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer
E. Bajetta et al.
ANNALS OF ONCOLOGY (2014)
Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy
Zheng Li et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Combination of microtubule associated protein-tau and β-tubulin III predicts chemosensitivity of paclitaxel in patients with advanced gastric cancer
Jingwei Yu et al.
EUROPEAN JOURNAL OF CANCER (2014)
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
Hugo E. R. Ford et al.
LANCET ONCOLOGY (2014)
Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue
Daniel V. T. Catenacci et al.
PLOS ONE (2014)
Genetic markers for prediction of treatment outcomes in ovarian cancer
E. Caiola et al.
PHARMACOGENOMICS JOURNAL (2014)
Adjuvant chemotherapy for gastric cancer: Current evidence and future challenges
Rosalba Miceli et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer
Jun-Eul Hwang et al.
BMC CANCER (2013)
Application of Selected Reaction Monitoring for Multiplex Quantification of Clinically Validated Biomarkers in Formalin-Fixed, Paraffin-Embedded Tumor Tissue
Todd Hembrough et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2013)
Evidence for predictive role of BRCA1 and bTUBIII in gastric cancer
Vladimir M. Moiseyenko et al.
MEDICAL ONCOLOGY (2013)
Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials
T. Reiman et al.
ANNALS OF ONCOLOGY (2012)
Publication of Tumor Marker Research Results: The Necessity for Complete and Transparent Reporting
Lisa M. McShane et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel
Jing Gao et al.
BMC CANCER (2011)
Expressions of thymidylate synthase, thymidine phosphorylase, class III β-tubulin, and excision repair cross-complementing group 1 predict response in advanced gastric cancer patients receiving capecitabine plus paclitaxel or cisplatin
Ming Lu et al.
CHINESE JOURNAL OF CANCER RESEARCH (2011)
Class III β-Tubulin (TUBB3): More than a Biomarker in Solid Tumors?
M. Mariani et al.
CURRENT MOLECULAR MEDICINE (2011)
Drugs That Target Dynamic Microtubules: A New Molecular Perspective
Richard A. Stanton et al.
MEDICINAL RESEARCH REVIEWS (2011)
Class III β-Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy
Guillaume Ploussard et al.
CANCER RESEARCH (2010)
Randomized Clinical Trials With Biomarkers: Design Issues
Boris Freidlin et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial
Ilfet Songun et al.
LANCET ONCOLOGY (2010)
Class III β-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma
Y. Koh et al.
ANNALS OF ONCOLOGY (2009)
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Richard M. Simon et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance
Edith A. Perez
MOLECULAR CANCER THERAPEUTICS (2009)
Proteomic analysis of laser-captured paraffin-embedded tissues: A molecular portrait of head and neck cancer progression
Vyomesh Patel et al.
CLINICAL CANCER RESEARCH (2008)
Class III β-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel
Carlos M. Galmarini et al.
CLINICAL CANCER RESEARCH (2008)
Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents?
Pascal Seve et al.
LANCET ONCOLOGY (2008)
Class III β-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer:: Analysis of NCIC JBR.10
Pascal Seve et al.
CLINICAL CANCER RESEARCH (2007)
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel
P Sève et al.
MOLECULAR CANCER THERAPEUTICS (2005)
βIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability
K Kamath et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Share Paper
